Magnetic Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia
Transcranial Magnetic Stimulation Used to Treat Auditory Hallucinations in Schizophrenia
1 other identifier
interventional
10
1 country
2
Brief Summary
Schizophrenia is a chronic, severe, and disabling brain disease. Auditory hallucinations are the most frequent symptoms with an incident of 50% to 70% in patients. Transcranial Magnetic Stimulation (TMS) can significantly reduce symptoms of schizophrenia. TMS is capable of inducing changes in the electrical activities of the brain in humans. The purpose of this trial is to study the use of TMS to decrease auditory hallucinations in schizophrenia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_4 schizophrenia
Started Nov 2004
Longer than P75 for phase_4 schizophrenia
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2004
CompletedFirst Submitted
Initial submission to the registry
September 13, 2005
CompletedFirst Posted
Study publicly available on registry
September 16, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2015
CompletedJuly 28, 2011
July 1, 2011
7.2 years
September 13, 2005
July 27, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Hoffman Auditory Hallucination Scale
A series of 7 questions to identify the intensity and severity of the hallucinations
weekly
Secondary Outcomes (1)
Positive and Negative Syndrome Scale for Schizophrenia (PANSS)
2 weeks
Study Arms (2)
True Transcranial Magnetic Stimulation
ACTIVE COMPARATORTrue treatment with TMS over the temporoparietal cortex.
Sham Transcranial Magnetic Stimulation
SHAM COMPARATORSham treatment with rTMS over the temporoparietal cortex.
Interventions
True treatment with rTMS over the temporoparietal cortex.
Eligibility Criteria
You may qualify if:
- Schizophrenia
- Auditory hallucinations occuring more than 5 times per day
- Adequate (6 weeks) trial of antipsychotic medication
- Including at least 1 atypical antipsychotic medication
- Medication stable for 4 weeks prior to commencement of the study
- Competent to consent
You may not qualify if:
- history of seizure disorder in patient or first degree relative
- recent head injury
- Acute suicidality
- Alcohol or substance abuse
- Implanted pacemaker or metal in head or neck
- Pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
St. Joseph's Healthcare, rTMS Laboratory, 100 West Fifth Street
Hamilton, Ontario, L8N 3K7, Canada
St. Joseph's Healthcare, rTMS Laboratory, 100 West Fifth Street
Hamilton, Ontario, L8N 3K7, Canada
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Gary Hasey, MD
St. Joseph's Health Care London
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
September 13, 2005
First Posted
September 16, 2005
Study Start
November 1, 2004
Primary Completion
January 1, 2012
Study Completion
January 1, 2015
Last Updated
July 28, 2011
Record last verified: 2011-07